All News
Allergic Drug-Induced Arthritis (5.19.2023)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. This week we delve into some odd associations, repeat drug warnings and the consequences of antirheumatic therapies.
Read Article
Microbiome of Hip and Knee Osteoarthritis is not "Sterile"
Next-generation DNA sequencing (NGS) techniques show the presence of bacterial DNA in surgical specimens of hip and knee arthritis, from patients undergoing first-time total joint arthroplasty, reports a study in The Journal of Bone & Joint Surgery.
Read Article
Peresolimab's Potential in Rheumatoid Arthritis
Peresolimab is a humanized IgG1 monoclonal antibody that acts as a programmed cell death protein 1 (PD-1) agonist (stimulator). The NEJM reports that PER met its efficacy primary endpont in treating patients with active rheumatoid arthritis (RA).
Read Article
MSK Symptoms from Dupilimab, an IL-4/13 Inhibitor
A new MSK syndrome of inflammatory enthesitis/arthritis/tenosynovitis has been described in atopic dermatitis (AD) patients treated with the IL-4 receptor antagonist, dupilumab.
Read Article
Brepocitinib in Active Psoriatic Arthritis
Brepocitinib is a novel tyrosine kinase 2/Janus kinase 1 inhibitor and has been studied in patients with moderately-to-severely active psoriatic arthritis (PsA), showing impressive efficacy at both 16 weeks and 52 weeks.
Read Article
Evidence-Based Guidelines for EGPA
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare form of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, affecting between 10 and 14 cases per million globally. This adult disorder has a mean age at diagnosis of nearly 50 years and affects both sexes equally, presenting with pulmonary symptoms (asthma), eosinophilia and granulomatous or vasculitic involvement of several organs. A multidisciplinary, multinational European group has developed evidence-based, guidelines for the diagnosis and management of EGPA, intended to include recent advances.
Read Article
RELIEF Trial: Sublingual Cyclobenzaprine in Fibromyalgia
Fibromyalgia patients hoping to see a more effective and convenient formulation of cyclobenzaprine at their local pharmacies must wait for an ongoing phase III trial -- the product's third -- to finish, as the first two delivered mixed results.
Read Article
Juvenile and Adult-onset Scleroderma Differ
A retrospecitve cohort comparision of juvenile (jSSc) and adult-onset (aSSc) systemic sclerosis (SSc) are both rare but present differently.
Read Article
Disappointing Secondary Use of Newer Therapies in Psoriatic Arthritis
Analysis of patient data from five Nordic registries shows that the uptake of newer biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in psoriatic arthritis (PsA) was mainly in biologic-experienced patients.
Read Article
2022 EULAR Recommendations on Screening and Prophylaxis for Opportunistic Infections
Opportunistic and chronic infections may be rare and are often difficult to diagnose, especially in patients with autoimmune inflammatory rheumatic diseases (AIIRD), that may be immunocompromised.
Read Article
Low Risk of Venous Thromboembolism with IVIG and Dermatomyositis
A cohort study analyzed the risk of venous thromboembolism (VTE) in dermatomyositis (DM) patients treated with intravenous immunoglobulin (IVIG).
Read Article
2010 Colchicine Price Hikes Adversely Affected Gout Care
Researchers from Harvard have reported their analysis showing that the large increase in colchicine cost in 2010 was associated with an immediate decrease in colchicine prescription use, with a 10 year increase in emergency department and rheumatology gout visits suggesting poorer gout control.
Read Article
B-Cell Stimulating Factors Tied to Lymphoma in Sjogren's
Genetic blood tests indicated that Bruton's tyrosine kinase (BTK) and a cytokine called APRIL were overexpressed in patients with primary Sjögren's syndrome who subsequently developed lymphoma, French researchers reported, suggesting that BTK inhibitors might be useful in this population.
Read Article
ICYMI: Psoriatic Arthritis and Pregnancy
Dr. Christina Chambers, an epidemiologist at the University of California San Diego and the principal investigator of MotherToBaby Pregnancy Studies, reviewed the available data on psoriatic arthritis and pregnancy. There is little evidence at this time that pregnancy affects PsA, though studies reliably demonstrate increase in disease activity in the post-partum period in both skin and joint disease.
Read Article
One in Ten has Autoimmune Disease
A UK population-based study suggests that autoimmune diseases affect approximately one in ten individuals.
Read Article
Prevalence and Mortality of IgG4-related disease in the USA
A current review of the epidemiology of IgG4-related disease (IgG4-RD) in the USA shows a low prevalence with possibly increasing numbers, owing to increasing awareness of this unique immune-mediated condition.
Read Article
Lupus During Pregnancy Carries Higher Maternal, Fetal Morbidity Risks
Women with systemic lupus erythematosus (SLE) had higher risks for maternal and fetal morbidity compared to those without the chronic autoimmune disorder, according to a nationwide analysis of U.S. data.
Read Article
Links:
Links:
Links:
